GALLIUM GA 68 GOZETOTIDE (gallium ga-68 gozetotide) by Francis Medical is positron emitting activity [moa]. First approved in 2020.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
Gallium GA-68 Gozetotide is a positron-emitting radioactive diagnostic agent administered intravenously as a solution. It functions as a molecular imaging tool leveraging positron emission for diagnostic visualization. The product targets patients requiring advanced imaging assessment across oncology and other diagnostic indications.
The product is in peak commercial phase with moderate competitive pressure (30%), suggesting stable market position and potential for specialized medical sales and clinical support roles.
Positron Emitting Activity
Radioactive Diagnostic Agent
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Working on Gallium GA-68 Gozetotide offers career opportunities in specialized diagnostic imaging commercialization, with focus on hospital and imaging center relationships. This role suits professionals with nuclear medicine, diagnostic imaging, or specialized medical device/pharmaceutical backgrounds seeking impact in diagnostic oncology and imaging markets.
Worked on GALLIUM GA 68 GOZETOTIDE at Francis Medical? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.